Singapore, April 14 -- ACRO Biomedical Co. has announced that itsABCcollaCollagen Ophthalmic Matrixhas received regulatory approval fromTaiwan'sMinistry of Health and Welfare (MoHW). This milestone marks a significant advancement in regenerative medicine and provides new hope for millions awaiting corneal transplants worldwide.

ABCcollaCollagen Ophthalmic Matrix is the world's first and only product to utilisesupercritical carbon dioxide decellularization technology, ensuring the complete removal of cells and impurities from animal-derived corneal tissue while preserving its intact collagen scaffold. This innovative approach enhancesbiocompatibility, biodegradability, and tissue regeneration. The product has receivedpatents in 15 countri...